Acquaviva C, Ferrara P, Bossis G, Brockly F, Salvat C, Jariel-Encontre I, Piechaczyk M
Institut de Génétique Moléculaire de Montpellier, UMR5535/IFR24, 1919, Montpellier, France.
Biochimie. 2001 Mar-Apr;83(3-4):357-62. doi: 10.1016/s0300-9084(01)01243-3.
c-Fos proto-oncoprotein is a short-lived transcription factor with oncogenic potential. We have shown that it is massively degraded by the proteasome in vivo under various experimental conditions. Other proteolytic systems including lysosomes and calpains, might, however, also marginally operate on it. Although there is evidence that c-Fos can be ubiquitinylated in vitro, the unambiguous demonstration that ubiquitinylation is necessary for its addressing to the proteasome in vivo is still lacking. c-Jun, one of the main dimerization partners of c-Fos within the AP-1 transcription complex, is also an unstable protein. Its degradation is clearly proteasome- and ubiquitin-dependent in vivo. Interestingly, several lines of evidence indicate that the addressing of c-Fos and c-Jun to the proteasome is, at least in part, governed by different mechanisms. c-Fos has been transduced by two murine osteosarcomatogenic retroviruses under mutated forms which are more stable and more oncogenic. The stabilization is not simply accounted for by simple deletion of c-Fos main destabilizer but, rather, by a complex balance between opposing destabilizing and stabilizing mutations. Though mutations in viral Fos proteins confer full resistance to proteasomal degradation, stabilization is limited because mutations also entail sensitivity to an unidentified proteolytic system. This observation is consistent with the idea that Fos-expressing viruses have evolved to ensure control protein levels to avoid high protein accumulation-linked apoptosis. In conclusion, the unveiling of the complex mechanism network responsible for the degradation of AP-1 family members is still at its beginning and a number of issues regarding the regulation of this process and the addressing to the proteasome are still unresolved.
c-Fos原癌蛋白是一种具有致癌潜力的短命转录因子。我们已经表明,在各种实验条件下,它在体内会被蛋白酶体大量降解。然而,包括溶酶体和钙蛋白酶在内的其他蛋白水解系统可能也会对其有少量作用。尽管有证据表明c-Fos在体外可被泛素化,但仍缺乏明确证据证明泛素化对于其在体内靶向蛋白酶体是必需的。c-Jun是AP-1转录复合物中c-Fos的主要二聚化伙伴之一,也是一种不稳定蛋白。其降解在体内显然依赖于蛋白酶体和泛素。有趣的是,几条证据表明,c-Fos和c-Jun靶向蛋白酶体至少部分受不同机制调控。c-Fos已被两种鼠骨肉瘤致瘤逆转录病毒以更稳定且更具致癌性的突变形式转导。这种稳定化并非简单地由c-Fos主要去稳定剂的简单缺失所致,而是由相反的去稳定化和稳定化突变之间的复杂平衡所导致。尽管病毒Fos蛋白中的突变赋予了对蛋白酶体降解的完全抗性,但稳定化是有限的,因为突变也导致对一种未知蛋白水解系统敏感。这一观察结果与表达Fos的病毒已经进化以确保控制蛋白水平以避免高蛋白积累相关凋亡的观点一致。总之,负责AP-1家族成员降解的复杂机制网络的揭示仍处于起步阶段,关于这一过程的调控以及靶向蛋白酶体的许多问题仍未解决。